The two companies were already partnered on a multiple myeloma CAR-T treatmentGilead Sciences said Monday it is acquiring Arcellx in a deal worth $7.8 billion, merging two biotech companies already co-developing a CAR-T therapy for multiple myeloma. The transaction values Arcellx at $115 per share, or a 79% premium to the stock’s Friday close. Arcellx […]
